References
- Novembre J, Galvani AP, Slatkin M. The geographic spread of the CCR5 Δ32 HIV-resistance allele. PLoS Biol 2005; 3: e339
- Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382: 722–725
- Kohem CL, Brenol JC, Xavier RM, Bredemeier M, Brenol CV, Dedavid e Silva TL, et al. The chemokine receptor CCR5 genetic polymorphism and expression in rheumatoid arthritis patients. Scand J Rheumatol 2007; 36: 359–364
- Volin MV, Shah MR, Tokuhira M, Haines GK, Woods JM, Koch AE. RANTES expression and contribution to Mo chemotaxis in arthritis. Clin Immunol Immunopathol 1998; 89: 44–53
- Lindner E, Nordang GB, Melum E, Flato B, Selvaag AM, Thorsby E, et al. Lack of association between the chemokine receptor 5 polymorphism CCR5Δ32 in rheumatoid arthritis and juvenile idiopathic arthritis. BMC Med Genet 2007; 8: 33
- Prahalad S. Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: A meta-analysis. Genes Immun 2006; 7: 264–268
- Garred P, Madsen HO, Petersen J, Marquart H, Hansen TM, Freiesleben Sorensen S, et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 1998; 25: 1462–1465
- Scheibel I, Veit T, Neves AG, Souza L, Prezzi S, Machado S, et al. Differential CCR5Delta32 allelic frequencies in juvenile idiopathic arthritis subtypes: Evidence for different regulatory roles of CCR5 in rheumatological diseases. Scand J Rheumatol 2008; 37: 13–17
- Bauer JW, Baechler EC, Petri M, Batliwalla FM, Crawford D, Ortmann WA, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human SLE. PLoS Med 2006; 3: e491
- Kaneko H, Ogasawara H, Naito T, Akimoto H, Lee S, Hishikawa T, et al. Circulating levels of β-chemokines in SLE. J Rheumatol 1999; 26: 568–573
- Mamtani M, Rovin B, Brey R, Camargo JF, Kulkarni H, Herrera M, et al. CCL3L1 gene-containing segmental duplications and polymorphisms in CCR5 affect risk of systemic lupus erythaematosus. Ann Rheum Dis 2008; 67: 1076–1083
- Gomez-Reino JJ, Pablos JL, Carreira PE, Santiago B, Serrano L, Vicario JL, et al. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum 1999; 42: 989–992
- Aguilar F, Nunez-Roldan A, Torres B, Wichmann I, Sanchez-Roman J, Gonzalez-Escribano MF. Chemokine receptor CCR2/CCR5 polymorphism in Spanish patients with SLE. J Rheumatol 2003; 30: 1770–1774
- Perez de LG, Maier H, Nieto E, Vielhauer V, Luckow B, Mampaso F, et al. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J Am Soc Nephrol 2001; 12: 1369–1382
- Segerer S, Mack M, Regele H, Kerjaschki D, Schlondorff D. Expression of the C-C chemokine receptor 5 in human kidney diseases. Kidney Int 1999; 56: 52–64
- Yamada M, Yagita H, Inoue H, Takanashi T, Matsuda H, Munechika E, et al. Selective accumulation of CCR4+T lymphocytes into renal tissue of patients with lupus nephritis. Arthritis Rheum 2002; 46: 735–740
- Anders HJ, Vielhauer V, Schlondorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int 2003; 63: 401–415
- Lieberman-Blum SS, Fung HB, Bandres JC. Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 2008; 30: 1228–1250
- Turner JE, Steinmetz OM, Stahl RA, Panzer U. Targeting of Th1-associated chemokine receptors CXCR3 and CCR5 as therapeutic strategy for inflammatory diseases. Mini Rev Med Chem 2007; 7: 1089–1096
- Anders HJ, Frink M, Linde Y, Banas B, Wornle M, Cohen CD, et al. CC chemokine ligand 5/RANTES chemokine antagonists aggravate glomerulonephritis despite reduction of glomerular leukocyte infiltration. J Immunol 2003; 170: 5658–5666